Among new treatment approaches for patients with cancer, few have accelerated as quickly
as neoadjuvant immune checkpoint blockade (ICB). Neoadjuvant cancer therapy is …

Immune checkpoint inhibitors (ICI) may overcome cancer cells' ability to evade the immune
system and proliferate. The long-term benefit of ICI in the metastatic setting led to evaluate …

BACKGROUND Immunotherapies that target the interaction of programmed death 1 (PD-1)
with its ligands, PD-L1 and PD-L2, have ushered in the modern oncology era. The PD-1 …

Neoadjuvant immunotherapy involves administering immune checkpoint inhibitors before
surgical resection in high-risk resectable disease. This strategy was shown to have a high …

The idea of usingthe immune system to treat cancer is an old concept. The approach of
relying on an immune response against a bacterial component to stimulate an anti-tumor …

Neoadjuvant checkpoint inhibition, in which the therapy is administered before surgery, is a
promising new approach to managing bulky but resectable melanoma, and is also being …

Immune checkpoint inhibition (ICI) immunotherapy has revolutionized the approach to
metastatic non-small-cell lung cancer (NSCLC). In particular, antibodies blocking the …

Introduction The combination of programmed cell death protein-1 or programmed death-
ligand 1 immune checkpoint blockade and chemotherapy has revolutionized the treatment …

Immune checkpoint blockade (ICB) improves outcomes for some patients with advanced or
metastatic cancers. Despite demonstrable progress, many patients do not respond to ICB …

Over the past decade, immune checkpoint blockade (ICB) therapy has revolutionized the
outlook for oncology with significant and sustained improvement in the overall patient …